ArticleGastroenterology report2017
Serum albumin predicts survival in patients with hilar cholangiocarcinoma.
Article in Gastroenterology report, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 28 citations in OpenAlex.
- Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial.The Lancet. Oncology · 2021Trial
- Observational
- Impact of Multimodal Oncological Therapy on Survival and Local Control in Unresectable Perihilar Cholangiocarcinoma.Cancer medicine · 2026Article
- The albumin-bilirubin score predicts outcomes in advanced biliary tract cancer treated with durvalumab immunochemotherapy.The oncologist · 2026Article
- Clinical Outcome of Endoscopic Transpapillary Drainage for Biliary Obstruction Due to Non-Hepato-Pancreato-Biliary Cancer: A Two-Center Retrospective Cohort Study.Clinics and practice · 2026Article
- Prognostic impact of albumin-bilirubin score in predicting the long-term survival of distal cholangiocarcinoma after radical surgery.World journal of surgical oncology · 2025Article
- Clinical features and prediction of long-term survival after surgery for perihilar cholangiocarcinoma.PloS one · 2024Article
- Article
- Article
- High expression of protein tyrosine phosphatase receptor S (PTPRS) is an independent prognostic marker for cholangiocarcinoma.Frontiers in public health · 2022Article
- Use of the Advanced Lung Cancer Inflammation Index as a Prognostic Indicator for Patients With Cholangiocarcinoma.Frontiers in surgery · 2022Article
- Treatment Outcomes of Advanced Cholangiocarcinoma: A Single-Center Experience from India.South Asian journal of cancer · 2022Article
- Development and validation of a 90-day mortality prediction model following endobiliary drainage in patients with unresectable malignant biliary obstruction.Frontiers in oncology · 2022Article
- Vascular invasion and lymph node metastasis mediate the effect of CA242 on prognosis in hilar cholangiocarcinoma patients after radical resection.Frontiers in oncology · 2022Article
- Nerve Fibers in the Tumor Microenvironment as a Novel Biomarker for Oncological Outcome in Patients Undergoing Surgery for Perihilar Cholangiocarcinoma.Liver cancer · 2021Article
- Use of preoperative controlling nutritional status (CONUT) score as a better prognostic marker for distal cholangiocarcinoma after pancreatoduodenectomy.Surgery today · 2021Article
- Distant Metastases in Patients with Intrahepatic Cholangiocarcinoma: Does Location Matter? A Retrospective Analysis of 370 Patients.Journal of oncology · 2020Article
- Biliary stenting alone versus biliary stenting combined withScientific reports · 2019Article
- Association of serum albumin level with incidence and mortality of overt hepatic encephalopathy in cirrhosis during hospitalization.Therapeutic advances in gastroenterology · 2019Article
- Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsHilar cholangiocarcinoma is a devastating malignancy with incidence varying by geography and other risk factors. Rapid progression of disease and delays in diagnosis restrict the number of patients eligible for curative therapy. The objective of this study was to determine prognostic factors of overall survival in all patients presenting with hilar cholangiocarcinoma.
methodsAll adult patients with histologically confirmed hilar cholangiocarcinoma from 2003 to 2013 were evaluated for predictors of survival using demographic factors, laboratory data, symptoms and radiological characteristics at presentation.
resultsA total of 116 patients were identified to have pathological diagnosis of hilar cholangiocarcinoma and were included in the analysis. Patients with a serum albumin level >3.0 g/dL (P < 0.01), cancer antigen 19-9 ≤200 U/mL (P = 0.03), carcinoembryonic antigen ≤10 ìg/L (P < 0.01) or patients without a history of cirrhosis (P < 0.01) or diabetes (P = 0.02) were associated with a greater length of overall survival. A serum albumin level >3.0 g/dL was identified as an independent predictor of overall survival (hazard ratio 0.31; 95% confidence interval 0.14-0.70) with a survival benefit of 44 weeks.
conclusionThis study was the largest analysis to date of prognostic factors in patients with hilar cholangiocarcinoma. A serum albumin level >3.0 g/dL conferred an independent survival advantage with a significantly greater length of survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.